Page last updated: 2024-11-05

meturedepa

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

meturedepa: structure in Merck Index, 9th ed, #6031 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15456
CHEMBL ID280685
CHEBI ID135138
SCHEMBL ID11711
MeSH IDM0082174

Synonyms (41)

Synonym
[bis(2,2-dimethyl-1-aziridinyl)phosphinyl]carbamic acid ethyl ester
carbamic acid,2-dimethyl-1-aziridinyl)-phosphinyl]-, ethyl ester
nsc-51325
dimethylurethimine
nsc51325
ethyl bis(2,2-dimethyl-1-aziridinyl)phosphorylcarbamate
meturedepa
ab-132
carbamic acid, [bis(2,2-dimethyl-1-aziridinyl)-phosphinyl]-, ethyl ester
ethyl [bis(2,2-dimethyl-1-aziridinyl)phosphinyl]carbamate
ab 132
carbamic acid, [bis(2,2-dimethyl-1-aziridinyl)phosphinyl]-, ethyl ester
[bis(2,2-dimethyl-1-aziridinyl)phosphinyl]carbamic acid, ethyl ester
ethyl n-[bis(2,2-dimethylethylenimido)phosphoro]carbamate
bis(2,2-dimethylaziridinyl)phosphinylurethane
turloc
ethyl n-bis(2,2-dimethylaziridin-1-yl)phosphorylcarbamate
1661-29-6
meturedepa (usan/inn)
D05018
CHEBI:135138
CHEMBL280685
(bis(2,2-dimethyl-1-aziridinyl)phosphinyl)carbamic acid, ethyl ester
ai3-50452
ethyl (bis(2,2-dimethyl-1-aziridinyl)phosphinyl)carbamate
meturedepum
ethyl n-(bis(2,2-dimethylethylenimido)phosphoro)carbamate
carbamic acid, (bis(2,2-dimethyl-1-aziridinyl)phosphinyl)-, ethyl ester
meturedepa [usan:inn]
43255365if ,
unii-43255365if
nsc 51325
meturedepum [inn-latin]
meturedepa [usan]
meturedepa [mi]
meturedepa [inn]
SCHEMBL11711
Q27258602
ethyl [bis(2,2-dimethylaziridin-1-yl)phosphoryl]carbamate
DTXSID60862727
AKOS040748911
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphoramideA compound in which one or more of the OH groups of phosphoric acid have been replaced with an amino or substituted amino group. The term is commonly confined to the phosphoric triamides, P(=O)(NR2)3, since replacement of one or two OH groups produces phosphoramidic acids: P(=O)(OH)(NR2)2 , P(=O)(OH)2(NR2).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID153658Average weight change of mice was determined on day 6 after intraperitoneal injection on day 1 at a dose of 400 mg/kg following intraperitoneal implant of P388 leukemia cells in CDF1 mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents.
AID154114Antitumor activity was determined after intraperitoneal injection on day 1 at a dose of 50 mg/kg following intraperitoneal implant of P388 leukemia cells in CDF1 mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents.
AID153455Compound was evaluated for the antineoplastic activity against P388 leukemia at an optimal dose of 100 mg/kg administered intraperitoneally1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and properties of bis(2,2-dimethylaziridinyl)phosphinic amides: a series of new antineoplastic agents.
AID108693Average weight change on day 5 in mice infected by P-388 leukemia when treated with a dose of 400 mg/Kg of compound1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
AID154113Antitumor activity was determined after intraperitoneal injection on day 1 at a dose of 400 mg/kg following intraperitoneal implant of P388 leukemia cells in CDF1 mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents.
AID153659Average weight change of mice was determined on day 6 after intraperitoneal injection on day 1 at a dose of 50 mg/kg following intraperitoneal implant of P388 leukemia cells in CDF1 mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents.
AID120058Median survival time (MST) of treated mice infected by P-388 leukemia, as percent of the MST of untreated controls when treated with a dose of 400 mg/Kg of compound1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
AID108685Average weight change on day 5 in mice infected by P-388 leukemia when treated with a dose of 100 mg/Kg of compound1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
AID153654Average weight change of mice was determined on day 6 after intraperitoneal injection on day 1 at a dose of 200 mg/kg following intraperitoneal implant of P388 leukemia cells in CDF1 mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents.
AID121654In vivo antitumor activity against P-388 leukemia in CDF1 mice at 100 mg or 363 umol by ip administration expressed as median survival time of drug treated mice/median survival time of control mice x1001991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
AID108694Average weight change on day 5 in mice infected by P-388 leukemia when treated with a dose of 50 mg/Kg of compound1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
AID111370In vivo antitumor activity against P-388 leukemia in CDF1 mice at 400 mg or 1453 umol by ip administration expressed as average wt. change determined between day 0 and day 6 of experiment1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
AID111221In vivo antitumor activity against P-388 leukemia in CDF1 mice at 100 mg or 363 umol by ip administration expressed as average wt. change determined between day 0 and day 6 of experiment1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID108689Average weight change on day 5 in mice infected by P-388 leukemia when treated with a dose of 200 mg/Kg of compound1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
AID121800In vivo antitumor activity against P-388 leukemia in CDF1 mice at 400 mg or 1453 umol by ip administration expressed as median survival time of drug treated mice/median survival time of control mice x1001991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
AID111231In vivo antitumor activity against P-388 leukemia in CDF1 mice at 200 mg or 727 umol by ip administration expressed as average wt. change determined between day 0 and day 6 of experiment1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID121801In vivo antitumor activity against P-388 leukemia in CDF1 mice at 50 mg or 182 umol by ip administration expressed as median survival time of drug treated mice/median survival time of control mice x1001991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
AID153652Average weight change of mice was determined on day 6 after intraperitoneal injection on day 1 at a dose of 100 mg/kg following intraperitoneal implant of P388 leukemia cells in CDF1 mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents.
AID154110Antitumor activity was determined after intraperitoneal injection on day 1 at a dose of 200 mg/kg following intraperitoneal implant of P388 leukemia cells in CDF1 mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents.
AID120059Median survival time (MST) of treated mice infected by P-388 leukemia, as percent of the MST of untreated controls when treated with a dose of 50 mg/Kg of compound1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
AID154108Antitumor activity was determined after intraperitoneal injection on day 1 at a dose of 100 mg/kg following intraperitoneal implant of P388 leukemia cells in CDF1 mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents.
AID120050Median survival time (MST) of treated mice infected by P-388 leukemia, as percent of the MST of untreated controls when treated with a dose of 100 mg/Kg of compound1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
AID120054Median survival time (MST) of treated mice infected by P-388 leukemia, as percent of the MST of untreated controls when treated with a dose of 200 mg/Kg of compound1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
AID111371In vivo antitumor activity against P-388 leukemia in CDF1 mice at 50 mg or 182 umol by ip administration expressed as average wt. change determined between day 0 and day 6 of experiment1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
AID121790In vivo antitumor activity against P-388 leukemia in CDF1 mice at 200 mg or 727 umol by ip administration expressed as median survival time of drug treated mice/median survival time of control mice x1001991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (75.00)18.7374
1990's2 (16.67)18.2507
2000's1 (8.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]